212 related articles for article (PubMed ID: 29614715)
1. Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF
Camacho-Villegas TA; Mata-González MT; García-Ubbelohd W; Núñez-García L; Elosua C; Paniagua-Solis JF; Licea-Navarro AF
Mar Drugs; 2018 Mar; 16(4):. PubMed ID: 29614715
[TBL] [Abstract][Full Text] [Related]
2. Human TNF cytokine neutralization with a vNAR from Heterodontus francisci shark: a potential therapeutic use.
Camacho-Villegas T; Mata-Gonzalez T; Paniagua-Solis J; Sanchez E; Licea A
MAbs; 2013; 5(1):80-5. PubMed ID: 23221782
[TBL] [Abstract][Full Text] [Related]
3.
Millán-Gómez D; Dueñas S; Muñoz PLA; Camacho-Villegas T; Elosua C; Cabanillas-Bernal O; Escalante T; Perona A; Abia D; Drescher F; Fournier PGJ; Ramos MA; Mares RE; Paniagua-Solis J; Mata-Gonzalez T; Gonzalez-Canudas J; Hoffman RM; Licea-Navarro A; Sánchez-Campos N
Oncotarget; 2018 Jun; 9(46):28016-28029. PubMed ID: 29963259
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies for the identification and purification of vNAR domains and IgNAR immunoglobulins from the horn shark Heterodontus francisci.
Juarez K; Dubberke G; Lugo P; Koch-Nolte F; Buck F; Haag F; Licea A
Hybridoma (Larchmt); 2011 Aug; 30(4):323-9. PubMed ID: 21851231
[TBL] [Abstract][Full Text] [Related]
5. Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain.
Müller MR; Saunders K; Grace C; Jin M; Piche-Nicholas N; Steven J; O'Dwyer R; Wu L; Khetemenee L; Vugmeyster Y; Hickling TP; Tchistiakova L; Olland S; Gill D; Jensen A; Barelle CJ
MAbs; 2012; 4(6):673-85. PubMed ID: 23676205
[TBL] [Abstract][Full Text] [Related]
6. Synthetic libraries of shark vNAR domains with different cysteine numbers within the CDR3.
Cabanillas-Bernal O; Dueñas S; Ayala-Avila M; Rucavado A; Escalante T; Licea-Navarro AF
PLoS One; 2019; 14(6):e0213394. PubMed ID: 31206542
[TBL] [Abstract][Full Text] [Related]
7. Recombinant humanized anti-vascular endothelial growth factor monoclonal antibody efficiently suppresses laser-induced choroidal neovascularization in rhesus monkeys.
Ji WW; Yu DA; Yang P; Fang P; Cao YX; Li H; Xie N; Yan SS
Eur J Pharm Sci; 2017 Nov; 109():624-630. PubMed ID: 28916483
[TBL] [Abstract][Full Text] [Related]
8. Isolation and Characterization of Targeting-HBsAg VNAR Single Domain Antibodies from Whitespotted Bamboo Sharks (
Jiang X; Sun S; Li Z; Chen M
Mar Drugs; 2023 Apr; 21(4):. PubMed ID: 37103376
[TBL] [Abstract][Full Text] [Related]
9. Humanization of the Shark V
Zhang YF; Sun Y; Hong J; Ho M
Curr Protoc; 2023 Jan; 3(1):e630. PubMed ID: 36594750
[TBL] [Abstract][Full Text] [Related]
10. Cytoplasmic and periplasmic expression of recombinant shark VNAR antibody in Escherichia coli.
Leow HC; Fischer K; Leow YC; Braet K; Cheng Q; McCarthy J
Prep Biochem Biotechnol; 2019; 49(4):315-327. PubMed ID: 30767708
[TBL] [Abstract][Full Text] [Related]
11. Exploring shark VNAR antibody against infectious diseases using phage display technology.
Lim HT; Kok BH; Leow CY; Leow CH
Fish Shellfish Immunol; 2023 Sep; 140():108986. PubMed ID: 37541634
[TBL] [Abstract][Full Text] [Related]
12. Identification of Anti-TNFα VNAR Single Domain Antibodies from Whitespotted Bambooshark (
Zhao L; Chen M; Wang X; Kang S; Xue W; Li Z
Mar Drugs; 2022 Apr; 20(5):. PubMed ID: 35621957
[TBL] [Abstract][Full Text] [Related]
13. Isolation of highly selective IgNAR variable single-domains against a human therapeutic Fc scaffold and their application as tailor-made bioprocessing reagents.
Buschhaus MJ; Becker S; Porter AJ; Barelle CJ
Protein Eng Des Sel; 2019 Dec; 32(9):385-399. PubMed ID: 32119084
[TBL] [Abstract][Full Text] [Related]
14. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications.
Stahl A; Stumpp MT; Schlegel A; Ekawardhani S; Lehrling C; Martin G; Gulotti-Georgieva M; Villemagne D; Forrer P; Agostini HT; Binz HK
Angiogenesis; 2013 Jan; 16(1):101-11. PubMed ID: 22983424
[TBL] [Abstract][Full Text] [Related]
15. Shark Attack: high affinity binding proteins derived from shark vNAR domains by stepwise in vitro affinity maturation.
Zielonka S; Weber N; Becker S; Doerner A; Christmann A; Christmann C; Uth C; Fritz J; Schäfer E; Steinmann B; Empting M; Ockelmann P; Lierz M; Kolmar H
J Biotechnol; 2014 Dec; 191():236-45. PubMed ID: 24862193
[TBL] [Abstract][Full Text] [Related]
16. Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy.
Tokunaga CC; Mitton KP; Dailey W; Massoll C; Roumayah K; Guzman E; Tarabishy N; Cheng M; Drenser KA
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1884-92. PubMed ID: 24550366
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Peptides from
Dueñas S; Escalante T; Gasperin-Bulbarela J; Bernáldez-Sarabia J; Cervantes-Luévano K; Jiménez S; Sánchez-Campos N; Cabanillas-Bernal O; Valdovinos-Navarro BJ; Álvarez-Lee A; De León-Nava MA; Licea-Navarro AF
Toxins (Basel); 2023 Apr; 15(4):. PubMed ID: 37104207
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
19. Construction and next-generation sequencing analysis of a large phage-displayed V
Feng M; Bian H; Wu X; Fu T; Fu Y; Hong J; Fleming BD; Flajnik MF; Ho M
Antib Ther; 2019 Jan; 2(1):1-11. PubMed ID: 30627698
[No Abstract] [Full Text] [Related]
20. Bevacizumab revisited: its use in different mouse models of ocular pathologies.
Hollanders K; Van Bergen T; Van de Velde S; Sijnave D; Vandewalle E; Moons L; Stalmans I
Curr Eye Res; 2015 May; 40(6):611-21. PubMed ID: 25117905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
